Apexigen
focused on high priority phase combination trials | Apexigen
Company
Deck Type
Sector
Industry
Deck date
March 2022
Slide
13 of 28
Related slides by other companies
ATAI
Investor Presentation
March 2023
changes in beta power from dose to hour post dose placebo low doses high doses no significant change significant increase preliminary data subject to change phase dose dependent frontal was demonstrated providing evidence of target engagement and mechanism of action a a | ATAI
Genelux
Investor Presentation
December 2023
phase anti tumor activity as leading into combination a | Genelux
Oculis
Investor Presentation
April 2023
phase a positive results in | Oculis
BioAtla
Investor Presentation
August 2022
focused pipeline with broad applicability of differentiated cab assets designed to deliver near term value pay phase dosing | BioAtla
Other recent decks by Apexigen
See all presentations (2 decks)
Investor Presentation
September 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights